Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 26, 2021

Primary Completion Date

July 31, 2022

Study Completion Date

September 20, 2025

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

Acalabrutinib

Given PO

BIOLOGICAL

Ublituximab

Given IV

DRUG

Umbralisib

Given PO

Trial Locations (1)

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER